IL18 and cancer: Novel IL-15-based therapies have combined it in preclinical studies with other immunotherapeutic agents, such as monoclonal antibodies (rituximab, alemtuzumab), CD40 agents, cancer vaccines, and other cytokines (IL-12, IL-18, and IL-21) (82, 84).